Trade mark owner: Himalaya Global Holdings Ltd. Licensed user: The Himalaya Drug Company. Each tablet contains: Extracts: Bacopa monnieri – 136 mg. Centella asiatica – 70 mg. Withania somnifera – 52 mg. Evolvulus alsinoides – 52 mg. Nardostachys jatamansi – 52 mg. Valeriana wallichii – 50 mg. Embelia ribes – 50 mg. Prunus amygdalus – 50 mg. Acorus calamus – 42 mg. Terminalia chebula – 36 mg. Emblica officinalis – 36 mg. Tinospora cordifolia – 36 mg. Celastrus paniculatus – 32 mg. Oroxylum indicum – 32 mg. Powders: Bacopa monnieri – 80 mg. Mucuna pruriens – 18 mg. Elettaria cardamomum – 18 mg. Terminalia arjuna – 18 mg. Anethum sowa – 18 mg. Ipomoea digitata – 18 mg. Withania somnifera – 18 mg. Zingiber officinale – 14 mg. Terminalia belerica – 14 mg. Myristica fragrans – 14 mg. Syzygium aromaticum – 10 mg. Mukta pishti – 3 mg. Ayurvedic. Proprietary medicine. Worldwide since 1930. Registered Trade mark. www.himalayahealthcare.com. Indications: 1. Memory disturbances: Attention fluctuations. Concentration impairment. Language and learning disability. Alcohol addiction. 2. Behavioral disorders: Hyperkinetic states. Asocial behavior. Temper tantrums. Aggressive behavior. Enuresis. 3. Anxiety and stress related anxiety disorders. 4. Mental fatigue. 5. Speech defects. 6. Supportive therapy in mind to moderate mental retardation. 7. As an adjuvant in epilepsy, Alzheimer’s and Parkinson’s disease. Expiry date: three years from the date of manufacture. Route of administration: oral. Presentation: Tablet: sealed packs of 50 tablets. Syrup: pilfer-proof bottles of 100 ml. Only for reference by a registered medical practitioner, a hospital or a laboratory. Pharmaceutical form: tablets, syrup. Pharmacotherapeutic group: nootropic. Mode of action: Mentat improves mental functions by a modulation of the cholinergic and GABAergic neuro-transmission. By restoring the frontal cortical muscarinic and cholinergic receptor activities, Mentat improves the mental quotient, memory span, concentration ability and stress threshold. Mentat helps reduce the level of tribulin, an endogenous Mono Amine Oxidase inhibitor, that is elevated in various levels of anxiety. Mentat also ameliorates attention fluctuations and behavioral disorders. Mentat exhibits significant anti-parkinsonian activity by enhancing the dopamine post-synaptic receptor activity. The sedative and tranquilizing effects of Mentat offer protection against convulsions and are beneficial in insomnia. Mentat improves articulation and corrects speech defects.
